Ruud Dobber

Stories

AstraZeneca COPD drug cuts flare-ups across all patient types in late-stage trials

Announced regulatory review progress for tozorakimab

Millions of COPD patients who don't respond to current biologic treatments may soon have a new option. AstraZeneca's tozorakimab cut moderate-to-severe flare-ups by 29% to 34% in two late-stage trials, and unlike existing biologics, it worked across all blood eosinophil levels.

Updated 1 hour ago